Today we announced Q1 2024 earnings. Our year is starting strong, with solid financial results and pipeline progress. Thank you to our colleagues who make our success possible.

We congratulate our own David Glass, VP of Research and Postdoctoral Program Chair, who was elected as a member of National Academy of Sciences. This recognition highlights his distinguished research in mechanisms of skeletal muscle atrophy and hypertrophy. We're proud of David and his team!

2023 was a big year for us. What made it so special? Hear our co-Founders, Len Schleifer and George Yancopoulos, reflect on our progress, and explore more in our Year in Review (for investor audiences): bit.ly/49T3Bqo

We’re announcing a new collaboration with Mammoth Biosciences that pairs their ultracompact CRISPR editing systems with our innovative delivery technologies, expanding our targeted gene editing abilities across multiple tissue and cell types. Learn more: bit.ly/49QYPKb

We’re presenting new and updated data from our broad oncology and hematology pipeline at #ASCO2024 . Learn more about our presentations, which feature our novel investigational research approaches here: bit.ly/3Qj8ouB

Next week at ASGCT we will share data and insights into our progress in genetic medicines and our gene therapy auditory program. #ASGCT2024

At #AACR24 , we’re presenting data from our pivotal trial in relapsed/refractory multiple myeloma. Read about our latest findings.

As part of our commitment to ongoing research in advanced non-small cell lung cancer (NSCLC), we’ll be at #AACR24 sharing insights on the potential use of machine learning and real-world data to predict results of a key efficacy endpoint.

Sharing a regulatory update on our investigational medicine for two subtypes of B-cell non-Hodgkin lymphoma.

We are proud to announce the U.S. FDA approval of an age expansion treatment for heterozygous hypercholesterolemia (HeFH). This provides a new option for certain people living with this rare, inherited disorder that causes high levels of bad cholesterol. Read more.

At #AAD2024 , we’re on the ground sharing the latest research across 26 abstracts and 8 oral presentations, highlighting data across several dermatologic conditions.

Learn more now at: bit.ly/49YRXe4

The U.S. FDA accepted for priority review the application for our investigational medicine for COPD, a serious, debilitating disease that has not seen new treatment approaches in more than a decade.

CC: Sanofi US

The U.S. Food and Drug Administration (FDA) has accepted our Biologics License Application, granting Priority Review, for our investigational medicine in relapsed/refractory multiple myeloma that has progressed after at least three prior therapies.

The Ministry of Health, Labor and Welfare in Japan has approved medicine for chronic spontaneous urticaria (CSU), providing a new option for certain patients struggling to manage this debilitating skin disease. @Sanofi

We're committed to pushing the boundaries of science in the auditory space to help people living with hearing loss. Our pioneering genetic medicines research and technologies have the opportunity to accelerate potential treatments for hearing disorders. #ARO

Today at #ARO , we presented updated results from the first patient dosed in our Phase 1/2 CHORD trial. These early results offer insight into the potential of gene therapy for the treatment of otoferlin-related and other genetic hearing loss. bit.ly/3OpIkwT

Today we’re grateful to our 13,000 colleagues around the world for helping us achieve another strong quarter and full year of 2023. We’re proud of our scientific advancements, commercial strength of our diversified portfolio and our growing impact for patients.

The European Medicines Agency (EMA) accepted for review the Marketing Authorization Application for our investigational bispecific antibody to treat people living with relapsed/refractory multiple myeloma who have progressed after at least three prior lines of therapy.

Today we announced the formation of Regeneron Cell Medicines with the acquisition of @2Seventybio's pipeline of investigational immune cell therapies. This new R&D unit within Regeneron will advance cell therapies and combination approaches to address cancer and other diseases.

Breaking news: The U.S. FDA approved an age expansion for eosinophilic esophagitis ( #EoE ) medicine to treat more people living with the disease. Sanofi US